National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Lyrica® is indicated for the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
30/09/2013 25/10/2013 Reimbursement not recommended.

The NCPE do not recommend pregabalin as a cost effective treatment for neuropathic pain.

 Summary

Pharmacoeconomic Reassessment

Commenced Completed Outcome
10/11/2014 12/06/2015 Currently reimbursed – cost effective under certain assumptions.

Summary